Pfizer just beat Wall Street on earnings.
Then it told investors not to expect a much bigger 2026 than 2025.
That's a strange combo. A 5% Q1 revenue jump alongside a full-year forecast that lands somewhere between flat and slightly down.
The Q1 print was strong. The full-year story is something else.
Older blockbusters did most of the lifting. Eliquis, Pfizer's blood thinner, brought in $2.17B in sales, up 13% from a year earlier.
Cancer drug Padcev pulled in $591M, a 39% jump. The RSV shot added $180M, up 37%.
Recently launched and acquired products grew 22% from a year ago, the firm said.
Net income came in at $2.69B, just under last year's $2.97B. EPS, which is profit per share of stock, was 75 cents on an adjusted basis.
The result was a clean beat on both top and bottom lines.
Now the harder part. Pfizer's Covid franchise is shrinking fast.
Its Covid shot pulled in $232M for Q1, down 59%. Paxlovid, the antiviral pill, dropped 62% to $186M. Both came in well below analyst estimates.
The drug maker is bracing for a $1.5B drop in Covid product sales in 2026, plus another $1.5B drop from drugs losing market exclusivity.
That's about $3B of revenue walking out the door over the year.
To plug the hole, Pfizer is leaning on M&A and pipeline bets.
The $10B Metsera deal gives Pfizer a foothold in obesity. That's the fastest-growing drug market in pharma right now.
GLP-1 leaders Eli Lilly and Novo Nordisk dominate the space, but Pfizer is positioning Metsera's pipeline as a next-wave entry.
A late-stage trial result on a targeted lung cancer drug is also expected later this year. That's a possible catalyst the firm has flagged a few times already.
Pfizer also extended patent protection on Vyndamax, a treatment for a rare heart condition, until June 2031. The firm did this through settlement deals with three generic drug makers.
That keeps a high-margin franchise on the books for an extra five years.
Pfizer shares have been a tough hold for investors over the past two years. The stock has lagged most of its big pharma peers as Covid sales rolled off.
The dividend yield, which is the cash payment a stock pays as a share of its price, has stayed high. That's a sign investors are paying for income, not growth, while they wait for the pipeline to deliver.
A clean Q1 beat helps. So does a flat 2026 outlook with no big cuts.
For now, Pfizer remains a value name with a high yield, not a growth name. Investors are paid to wait while the firm rebuilds its top line.
The Q1 numbers say that wait isn't unrewarded. The 2026 number says it isn't over.
Investors will be tracking two things in 2026.
First, whether Pfizer's newer products can scale fast enough to offset the Covid and patent cliff.
Second, whether the Metsera deal puts Pfizer in real obesity-drug contention against Lilly and Novo.
Pfizer reaffirmed adjusted EPS of $2.80 to $3 for 2026.
The Q1 beat bought the firm time. The 2026 number tells you why it needs it.
